Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.37 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.37 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.37 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.37 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.37 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.37 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.37 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.37 |
| ▸ | PSMA5 | P28066 | 1/20 | 0.37 |
| ▸ | PSMB4 | P28070 | 1/20 | 0.37 |
| ▸ | PSMB6 | P28072 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | LONP1 | P36776 | 1/20 | 0.37 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.37 |
| ▸ | PSMB3 | P49720 | 1/20 | 0.37 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.37 |
| ▸ | PSMA6 | P60900 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10200511 | 0.90 | CA2 (0.45) | CA2TDP1PSMB11PSMA7PSMB1 | |
| SCHEMBL2736137 | 0.82 | CA2 (0.64) | CA2TDP1KMT2ACYP3A4KDM4E | |
| SCHEMBL13770954 | 0.77 | PSMB1 (0.47) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL13780660 | 0.74 | CYP3A4 (0.53) | CYP3A4 | |
| SCHEMBL19210477 | 0.74 | TDP1 (0.44) | TDP1KMT2ACYP3A4KDM4EALDH1A1 | |
| SCHEMBL2736135 | 0.72 | CYP3A4 (0.56) | CYP3A4 | |
| SCHEMBL13907814 | 0.72 | CYP3A4 (0.56) | CYP3A4 | |
| SCHEMBL2736136 | 0.72 | CYP3A4 (0.39) | CA2CYP3A4 | |
| SCHEMBL10305066 | 0.71 | TDP1 (0.46) | TDP1KMT2ACYP3A4KDM4EALDH1A1 | |
| SCHEMBL4683895 | 0.71 | CA2 (0.67) | CA2KMT2ACYP3A4ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221348-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-9891239-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170158647-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170143680-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2017-05-25 | — | — | US | disclosed |
| US-9575080-B2 | — | — | 2017-02-21 | — | — | US | disclosed |
| US-9575080-B2 | — | — | 2017-02-21 | — | — | US | disclosed |
| US-8759379-B2 | Inhibitors of cytochrome P450 | GILEAD SCIENCES, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8383655-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120237478-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-8148374-B2 | Concurrent administering of drugs; side effect reduction | GILEAD SCIENCES, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110212964-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7939553-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20100189687-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20090291952-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES,INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES,INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090175820-A1 | INHIBITORS OF CYTOCHROME P450 | GILEAD SCIENCES, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| WO-2008103949-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| US-20080207620-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080108617-A1 | co-administered drug (as HIV protease inhibiting compound, an HIV (non)nucleoside/nucleotide inhibitor of reverse transcriptase, capsid polymerization inhibitor, interferon, ribavirin analog) by inhibiting cytochrome P450 monooxygenase; ureido- or amido-amine derivatives; side effect reduction | GILEAD SCIENCES, INC. | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108617-A1 | co-administered drug (as HIV protease inhibiting compound, an HIV (non)nucleoside/nucleotide inhibitor of reverse transcriptase, capsid polymerization inhibitor, interferon, ribavirin analog) by inhibiting cytochrome P450 monooxygenase; ureido- or amido-amine derivatives; side effect reduction | PNP, UNG, PNPO | CA2 4415/4885TDP1 798/4885PSMB11 280/4885 |
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | SLC10A1, SLC10A2, SLC26A4 | CA2 1494/4885TDP1 3338/4885PSMB11 3179/4885 |
| US-20090175820-A1 | INHIBITORS OF CYTOCHROME P450 | CYP11B1, CYP11B2, CYP2F1 | CA2 919/4885TDP1 827/4885PSMB11 1876/4885 |
| US-20080207620-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | CA2 1559/4885TDP1 3285/4885PSMB11 3226/4885 |
| US-20100189687-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | CA2 1559/4885TDP1 3285/4885PSMB11 3226/4885 |
| US-20120237478-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | CA2 1559/4885TDP1 3285/4885PSMB11 3226/4885 |
| US-20180221348-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | CA2 1704/4885TDP1 2706/4885PSMB11 3038/4885 |
| US-20170158647-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | CA2 1559/4885TDP1 3285/4885PSMB11 3226/4885 |
| US-20170143680-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | CA2 1704/4885TDP1 2706/4885PSMB11 3038/4885 |
| US-20090291952-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | CA2 1704/4885TDP1 2706/4885PSMB11 3038/4885 |
| US-20110212964-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | CA2 1704/4885TDP1 2706/4885PSMB11 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.